Zimmer Biomet Keeps Changing Its Leaders. The Numbers Say the Business Is Getting Cleaner.

Zimmer Biomet is the kind of stock that tests your patience on purpose. Twice this year it reported results and raised its own guidance, and twice the good news got buried within hours by a change at the top. In April a chief financial officer stepped aside on the same day the company beat and guided up, and the shares dropped more than 10%to near $83 anyway. In September a reshuffle of the Americas leadership sent a recently hired senior executive out the door. The stock that touched a 52-week high near $107 now trades around $93, still down over the past year even after a bounce off a $79 low.

The market has an honest case for nervousness: this is a company whose top ranks have been in motion for three years. But a falling leadership résumé is not the same thing as a falling business, and it pays to check which one the stock is actually pricing. The headlines say churn. The cash-flow path says otherwise.

What the churn is sitting on top of

Strip away the personnel noise and the underlying operation has quietly done two consecutive quarters of what it said it would. In the June quarter, sales were $2.18 billion, up 4% on an organic, constant-currency basis, with adjusted earnings per share of $2.07. In April, sales rose about 3% organically and adjusted EPS jumped 15.5% to $2.09. Management has raised its full-year 2026 adjusted-EPS guidance twice, most recently to the $8.47–$8.59 range, and bumped its planned buyback to as much as $1 billion for the year.

That guidance number matters because of what it does to the valuation. At the current price near $93, guidance of roughly $8.50 in adjusted EPS puts Zimmer at about 11 times forward earnings. For a company that generates around $1.1 billion in trailing free cash flow — roughly a 6% yield on the market cap — trading under $94 is not a story about a broken business. It is a story about a market that has been burned by leadership and is now demanding proof of the operating path before it pays up. That is precisely the expectations-reset contrast the stock rewards when the numbers cooperate.

The free cash flow deserves a caveat in the same breath, because it is the honest part of this. Trailing twelve-month free cash flow is down about 6% from a year ago, dipped from a mid-2025 peak, and the company is spending more on capital now as it builds for the robot launch. So this is not a clean hockey-stick on cash. It is a stable $1.1 billion level with a credible path higher, and the discipline demands I say the path is more important than the current snapshot. When the proof point is cash and the cash is steady rather than inflecting, that carries real uncertainty and I treat it as such.

What gets better in the next twelve months

The operating setup improving underneath is not vague. The next-generation Monogram orthopedic robot is slated for 2027, and the September reshuffle was structured specifically around it — a new Americas robotics president is charged with expanding that sales force ahead of the launch. The newly cleared ROSA Shoulder system began its first cases this year. The parts of the portfolio growing fastest are the newer ones: sports medicine, extremities and trauma grew in the low single digits in the June quarter, while the technology, data and surgical line grew more than 20%. Even the laggard is the biggest unit — knees, roughly a third of revenue, grew just 0.1% organically — which is the honest reminder that this is a low-to-mid-single-digit grower, not a compounding machine, and that a rerating would be powered by margins, buyback and a fresh product cycle more than by the top line.

There is also a lap effect worth naming. Last year Zimmer absorbed $60 million to $80 million hit to operating profit from tariffs; that headwind is now in the base, so 2026 compares against it, and management lifted its revenue-growth outlook when it delivered the June quarter. None of this requires squinting. It just requires reading the earnings releases instead of the resignations.

Where the case breaks

The strongest bear argument is not the strategy — it is the people, and it deserves to be stated plainly. When a company cycles through a CEO, a CFO, and then a division president within three years, the market has a right to ask whether the churn is a symptom of deeper dysfunction, and a knee business that barely grew last quarter gives the skeptics a concrete hook. There is also integration and goodwill risk from the deals Zimmer has bought to diversify — its own April filing flagged a pending goodwill assessment that could hit reported earnings.

So the tripwire is specific. The thesis survives if guidance holds or rises, if free cash flow re-accelerates toward or past $1.2 billion, and if the Monogram robot launches on schedule in 2027 with commercial traction. The thesis breaks if management cuts guidance, if the cash stalls, or if the flagship robot slips — because then the churn stops looking cosmetic and starts looking like the tell. I can be wrong again, on either side. But a steady $1.1 billion cash machine trading around eleven times guided earnings, with a product catalyst a year away and the market still pricing the old leadership-risk story, is the kind of setup where discipline — and patience — tends to be rewarded.

This is not about excitement. It is about a business that may soon look a lot harder to dismiss once the free cash flow and the robot both show up.